Page 2,843«..1020..2,8422,8432,8442,845..2,8502,860..»

Stem cells in ovaries may grow new eggs, study shows

Posted: February 27, 2012 at 5:02 pm

(CBS/AP) Stem cells in young women's ovaries are capable of producing new eggs, according to a new study. The findings challenge 60 years of dogma that women are born with all the eggs they'll ever have.

PICTURES: Human eggs: 9 fascinating facts

For the study, published in the Feb. 26 issue of Nature Medicine and led by Jonathan Tilly of Massachusetts General Hospital, researchers examined healthy human ovaries donated by 20-something Japanese women who were undergoing a sex-change operation. The researchers fished out stem cells by searching for a protein found only on the surface of stem cells. The researchers then injected those stem cells into pieces of human ovary, transplanting the tissue under the skin of mice, to provide the tissue with a nourishing blood supply.

What happened? New egg cells formed within two weeks.

That's still a long way from showing they'll mature into usable, quality eggs, David Albertini, director of the University of Kansas' Center for Reproductive Sciences, cautioned.

Still, these findings could lead to better treatments for women left infertile because of disease - or simply because they're getting older.

"Our current views of ovarian aging are incomplete. There's much more to the story than simply the trickling away of a fixed pool of eggs," Tilly, who has long hunted these cells in a series of controversial studies, said.

Tilly's previous work has drawn skepticism, and independent experts urged caution about the latest findings, so the next step is to see whether other laboratories can verify the work. If the findings are confirmed, then it would take years of additional research to learn how to use the cells, Teresa Woodruff, fertility preservation chief at Northwestern University's Feinberg School of Medicine, said.

"This is experimental," Dr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore-LIJ Health System in Manhasset, N.Y., told HealthDay. He said the study is "exciting" but emphasized the work is still very preliminary. "This is a beginning of perhaps something that could bring in new opportunities, but it's going to be a long time in my estimation until clinically we'll be able to actually have human eggs created from stem cells that make babies."

Still, even a leading critic said such research may help dispel some of the enduring mystery surrounding how human eggs are born and mature.

"This is going to spark renewed interest, and more than anything else it's giving us some new directions to work in," Albertini said. While he has plenty of questions about the latest work, "I'm less skeptical," he said.

Scientists have long taught that all female mammals are born with a finite supply of egg cells, called ooctyes, that runs out in middle age. Tilly, Mass General's reproductive biology director, first challenged that notion in 2004, reporting that the ovaries of adult mice harbor some egg-producing stem cells. Recently, Tilly noted, a lab in China and another in the U.S. also have reported finding those rare cells in mice.

More work is needed to tell exactly what these cells are, cautioned reproductive biologist Kyle Orwig of the University of Pittsburgh Medical Center, who has watched Tilly's work with great interest.

But if they're really competent stem cells, Orwig asked, then why would women undergo menopause? Indeed, something so rare wouldn't contribute much to a woman's natural reproductive capacity, added Northwestern's Woodruff.

Tilly argues that using stem cells to grow eggs in lab dishes might one day help preserve cancer patients' fertility. Today, Woodruff's lab and others freeze pieces of girls' ovaries before they undergo fertility-destroying chemotherapy or radiation. They're studying how to coax the immature eggs inside to mature so they could be used for in vitro fertilization years later when the girls are grown. If that eventually works, Tilly says stem cells might offer a better egg supply.

View post:
Stem cells in ovaries may grow new eggs, study shows

Posted in Stem Cells | Comments Off on Stem cells in ovaries may grow new eggs, study shows

Stem Cells in Women’s Ovaries May Produce New Eggs, Study Finds

Posted: February 27, 2012 at 5:02 pm

Contrary to the belief that women are born with a finite number of eggs, there may in fact be a way to replenish the supply, a new study suggests.

Researchers have isolated stem cells from adult human ovaries that appear to be capable of producing eggs.

The new findings follow a number of recent studies that have suggested such stem cells exist in adult mice, and can give rise to healthy offspring in animals that have had their fertility destroyed by chemotherapy. However, these studies have been controversial, because they go against years of research suggesting otherwise, experts say.

In the new study, the researchers devised a more rigorous way to isolate these cells, and for the first time, suggested their existence in people.

If true, the findings could have  implications for women's fertility treatments. Currently, women who choose to undergo in vitro fertilization (IVF) for infertility must endure hormone injections so doctors can retrieve eggs for fertilization, said study researcher Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital. But if researchers could isolate egg-producing stem cells from ovaries, it might be possible to conduct that whole process outside the body, Tilly said.

"That whole program of IVF… becomes a non-necessity," Tilly said.

The study is published online today (Feb. 26) in the journal Nature Medicine.

Egg stem cells

In the new study, Tilly and colleagues isolated egg-producing stem cells from human ovary tissue by targeting a protein found on the surface of only these cells. In dishes, the cells grew into cells that had properties of human eggs. For instance, they had half the genetic material of other cells in the body.

Next, to show the stem cells could produce eggs, the researchers placed a gene into the stem cells that made them glow green, placed the stem cells into human ovarian tissue (taken during a biopsy), and grafted this tissue into mice. One to two weeks later, this tissue contained egg cells glowing green, showing they had formed from the stem cells, the researchers said.

The researchers don't yet know if these egg cells could be fertilized to produce children. The United States does not allow human eggs to be fertilized for research purposes. The researchers also don't know whether these egg-producing stem cells are active throughout a woman's life, or only when they receive a particular signal, Tilly said, although the researchers have a follow-up study planned to address this question.

The number of egg-producing stem cells appear to be quite minute. In mice, they make up about 0.014 percent of all cells in the ovary, Tilly said.

Still a controversy

"It's very novel and it's very exciting," said Dr. Sandra Carson, professor of obstetrics and gynecology, at Brown University's Women & Infants Hospital, who was not involved in the study.

"It certainly makes sense that there would be those stem cells still there," said Carson, noting men have stem cells that produce sperm throughout life.

However, other researchers say the new paper does not resolve the controversy of whether egg-producing cells exist in adult ovaries.

"I would like to see better characterization of this very small pool of cells that may be present in the ovary," said Dr. Marco Conti, professor and director of the Center for Reproductive Sciences at the University of California, San Francisco. Conti noted that some properties of the egg-producing cells described in this study do not match descriptions from previous studies.

And the paper still does not address whether these cells have any role in adult humans.

"There is no real functional evidence that this pool of cells indeed contributes to [egg formation] in the adult," Conti said.

But if these cells do in fact work in the way the researchers suspect, it might be possible to grow and mature them in an environment that resembles an ovary, Carson said.

In addition, unlike human eggs, these stem cells can be frozen without damage, Tilly said, so it may be possible to store them for future use.

Tilly is a co-founder of OvaScience, Inc, which has licensed the commercial potential of these findings for development of new fertility-enhancing procedures.

Pass it on:  Women's ovaries may contain stem cells that are capable of producing eggs after birth.

This story was provided by MyHealthNewsDaily, a sister site to LiveScience. Follow MyHealthNewsDaily staff writer Rachael Rettner on Twitter @RachaelRettner. Find us on Facebook.

Read more from the original source:
Stem Cells in Women's Ovaries May Produce New Eggs, Study Finds

Posted in Stem Cells | Comments Off on Stem Cells in Women’s Ovaries May Produce New Eggs, Study Finds

Stem Cells in Ovaries May Give Women More Eggs

Posted: February 27, 2012 at 5:02 pm

Contrary to the belief that women are born with a finite number of eggs, there may in fact be a way to replenish the supply, a new study suggests.

Researchers have isolated stem cells from adult human ovaries that appear to be capable of producing eggs.

ANALYSIS: Old Genes Making Hulking Ants

The new findings follow a number of recent studies that have suggested such stem cells exist in adult mice, and can give rise to healthy offspring in animals that have had their fertility destroyed by chemotherapy. However, these studies have been controversial, because they go against years of research suggesting otherwise, experts say.

In the new study, the researchers devised a more rigorous way to isolate these cells, and for the first time, suggested their existence in people.

If true, the findings could have implications for women's fertility treatments. Currently, women who choose to undergo in vitro fertilization (IVF) for infertility must endure hormone injections so doctors can retrieve eggs for fertilization, said study researcher Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital. But if researchers could isolate egg-producing stem cells from ovaries, it might be possible to conduct that whole process outside the body, Tilly said.

"That whole program of IVF… becomes a non-necessity," Tilly said.

The study is published online Feb. 26 in the journal Nature Medicine.

Egg Stem Cells

In the new study, Tilly and colleagues isolated egg-producing stem cells from human ovary tissue by targeting a protein found on the surface of only these cells. In dishes, the cells grew into cells that had properties of human eggs. For instance, they had half the genetic material of other cells in the body.

Next, to show the stem cells could produce eggs, the researchers placed a gene into the stem cells that made them glow green, placed the stem cells into human ovarian tissue (taken during a biopsy), and grafted this tissue into mice. One to two weeks later, this tissue contained egg cells glowing green, showing they had formed from the stem cells, the researchers said.

NEWS: Stems Cells Improve Vision in Two Blind Patients

The researchers don't yet know if these egg cells could be fertilized to produce children. The United States does not allow human eggs to be fertilized for research purposes. The researchers also don't know whether these egg-producing stem cells are active throughout a woman's life, or only when they receive a particular signal, Tilly said, although the researchers have a follow-up study planned to address this question.

The number of egg-producing stem cells appear to be quite minute. In mice, they make up about 0.014 percent of all cells in the ovary, Tilly said.

Still a Controversy

"It's very novel and it's very exciting," said Dr. Sandra Carson, professor of obstetrics and gynecology, at Brown University's Women & Infants Hospital, who was not involved in the study.

"It certainly makes sense that there would be those stem cells still there," said Carson, noting men have stem cells that produce sperm throughout life.

However, other researchers say the new paper does not resolve the controversy of whether egg-producing cells exist in adult ovaries.

"I would like to see better characterization of this very small pool of cells that may be present in the ovary," said Dr. Marco Conti, professor and director of the Center for Reproductive Sciences at the University of California, San Francisco. Conti noted that some properties of the egg-producing cells described in this study do not match descriptions from previous studies.

And the paper still does not address whether these cells have any role in adult humans.

"There is no real functional evidence that this pool of cells indeed contributes to [egg formation] in the adult," Conti said.

But if these cells do in fact work in the way the researchers suspect, it might be possible to grow and mature them in an environment that resembles an ovary, Carson said.

In addition, unlike human eggs, these stem cells can be frozen without damage, Tilly said, so it may be possible to store them for future use.

Tilly is a co-founder of OvaScience, Inc, which has licensed the commercial potential of these findings for development of new fertility-enhancing procedures.

More From HealthNewsDaily.com

Continue reading here:
Stem Cells in Ovaries May Give Women More Eggs

Posted in Stem Cells | Comments Off on Stem Cells in Ovaries May Give Women More Eggs

Angel Biotechnology – Grant of Share Options

Posted: February 27, 2012 at 5:01 pm

27 February 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Grant of Share Options - Enterprise Management Incentive (EMI) Scheme

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce share options totaling 16,806,723 were awarded to Dr. Stewart White, Commercial Director, under the Company's Enterprise Management Incentive (EMI) share option scheme on 24 February 2012. All share options are exercisable at a price of 0.238p per share, subject to performance and retention criteria being met and are the first share options awarded to Dr. White since his appointment last year.

The exercise dates are as follows:

Exercise Dates

Number of options

04/06/2012 - 03/06/2022

3,361,345

31/12/2012 - 30/12/2022

6,722,689

31/03/2013 - 30/03/2023

6,722,689

Dr Paul Harper, Executive Chairman of Angel Biotechnology Holdings plc said:

"The Board of Directors is delighted to award these options to Dr. White to reflect the commitment made to ensure the success of the Company."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director http://www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 (0) 20 7947 4350

Media (Frankfurt: 725292 - news) enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA).

Its (Euronext: ALITS.NX - news) customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle (Frankfurt: 725198 - news) -upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at http://www.angelbio.com .

- Ends -

Read this article:
Angel Biotechnology - Grant of Share Options

Posted in Biotechnology | Comments Off on Angel Biotechnology – Grant of Share Options

StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012

Posted: February 27, 2012 at 5:00 pm

NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is being held in Qatar from February 27 to March 1, 2012. The Company, which is the leader in development of cell-based therapeutics for central nervous system disorders, was specifically invited by the conference's sponsors, the State of Qatar and Amir of Qatar His Highness Sheikh Hamad bin Khalifa Al-Thani, as well as the James A. Baker III Institute for Public Policy of Rice University, and is the only company to be invited.

Ann Tsukamoto, Ph.D., StemCells' Executive Vice President, Research and Development, will make a presentation on the clinical translation of human neural stem cells. StemCells was the first company to receive authorization from the US Food and Drug Administration to conduct a clinical trial of purified human neural stem cells, and the Company is currently conducting two clinical trials with a third anticipated to start later this year. Dr. Tsukamoto will also be the moderator of the panel session on neurological disorders, which is scheduled to be held on March 1 from 9:30 a.m. to 11:00 a.m. Arabian Standard Time (AST).

In addition, Irving Weissman, M.D., Chairman of StemCells' Scientific Advisory Board, will make a keynote presentation to the conference on Tuesday, February 28 at 9:00 a.m. AST. Dr. Weissman, who is Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology and Professor of Developmental Biology at the Stanford School of Medicine, and Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine, will speak on normal and neoplastic stem cells. Dr. Weissman will also participate in a panel discussion on the opportunities and challenges for stem cell research, and will moderate a panel discussion on pluripotent stem cells.

The Qatar International Conference on Stem Cell Science and Policy will bring together more than 400 international participants from industry, academia and public policy, including leading experts from each of these sectors. The conference's objectives are to showcase the latest stem cell research from around the world, while promoting discussion and awareness of scientific, ethical and regulatory issues related to this innovative and dynamic field.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. The Company recently completed a clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, and expects to report the trial results soon. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury, and expects to initiate a Phase I/II clinical trial in dry age- related macular degeneration in the near future. In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Form 10-Q and Form 8-K.

See more here:
StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012

Posted in Cell Medicine | Comments Off on StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012

Nature: BrainStorm’s NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

Posted: February 27, 2012 at 5:00 pm

NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.

In the preclinical studies conducted by leading scientists including Professors Melamed and Offen of Tel Aviv University and originally reported in Experimental Neurology, patients' bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) that were transplanted into an animal model of Huntington disease showed therapeutic benefits.

Addressing the role of these MSC-NTF cells in Huntington disease, Professor Daniel Offen explains, "the premise is that such cells can be transplanted safely into affected areas of the brain, and thereby serve as vehicles for delivering neurotrophic factors." Offen expressed his hope that this cell-based therapy may eventually progress to the clinic.

BrainStorm is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results have shown that Brainstorm’s NurOwn™ therapy is safe, does not show any significant treatment-related adverse events, and have also shown certain signs of beneficial clinical effects.

Follow this link for the Research Highlights page in Nature Reviews Neurology (starts Feb. 28th ): http://www.nature.com/nrneurol/journal/vaop/ncurrent/index.html

To read the Original Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. follow this link: http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot (www.ramot.org) at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Read this article:
Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Nature: BrainStorm’s NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

Creating a burger from stem cells – Video

Posted: February 27, 2012 at 6:14 am

20-02-2012 17:34 Is getting your hamburger from a lab instead of an animal on the horizon? CNN's Mary Snow reports.

Read more from the original source:
Creating a burger from stem cells - Video

Posted in Stem Cell Videos | Comments Off on Creating a burger from stem cells – Video

Teeth 'transform into liver cells'

Posted: February 27, 2012 at 6:14 am

The compound that causes bad breath could help fuel the development of stem cells from dental pulp, according to a study.

Hydrogen sulphide (H2S) - which has the characteristic smell of rotten eggs - appears to help teeth stem cells transform into liver cells, which could prove a valuable treatment for patients, researchers found.

H2S is a major cause of halitosis or bad breath, which is of concern to millions of people worldwide.

A team of experts took stem cells from dental pulp - the central part of the tooth made up of connective tissue and cells - obtained from the teeth of dental patients undergoing routine tooth extractions.

The cells were separated into two groups, with one group incubated in a H2S chamber and the other group acting as a control. The cells were analysed after three, six and nine days to see if they had transformed into liver cells. Their ability to function as liver cells was also tested, including the ability to store glycogen and collect urea.

The study, published in the Journal of Breath Research, from the Institute of Physics, suggested liver cells could be produced in high numbers of high purity.

Lead author of the study, Dr Ken Yaegaki, from Nippon Dental University in Japan, said: "High purity means there are less 'wrong cells' that are being differentiated to other tissues, or remaining as stem cells. Moreover, these facts suggest that patients undergoing transplantation with the hepatic (liver) cells may have almost no possibility of developing teratomas (tumours) or cancers.

"Until now, nobody has produced the protocol to regenerate such a huge number of hepatic cells for human transplantation. Compared to the traditional method of using fetal bovine serum to produce the cells, our method is productive and, most importantly, safe."

Professor Anthony Hollander, head of cellular and molecular medicine at Bristol University, said much more research was needed.

He said: "This is interesting work in a new direction but there's a long way to go to see if it is usable therapeutically. This is potential evidence but the real test of the liver cell is whether it metabolises specific toxins," he said, adding that that requires enzyme function tests."

Go here to see the original:
Teeth 'transform into liver cells'

Posted in Stem Cell Videos | Comments Off on Teeth 'transform into liver cells'

Study finds stem cells can create human eggs

Posted: February 27, 2012 at 6:14 am

Researchers at Massachusetts General Hospital say they have extracted stem cells from human ovaries and made them generate egg cells. The advance, if confirmed, might provide a new source of eggs for treating infertility, though scientists say it is far too early to tell if the work holds such promise.

Women are born with a complement of egg cells that must last throughout life. The ability to isolate stem cells from which eggs could be cultivated would help not only with fertility but also with biologists' understanding of how drugs and nutrition affect the egg cells.

The new research, by a team led by the biologist Jonathan Tilly, depends on a special protein found to mark the surface of reproductive cells like eggs and sperm. Using a cell-sorting machine that can separate out the marked cells, the team obtained reproductive cells from mouse ovaries and showed that the cells would generate viable egg cells that could be fertilized and produce embryos.

They then applied the same method to human ovaries donated by women at the Saitama Medical Center in Japan who were undergoing sex reassignment because of a gender identity disorder. As with the mice, the team was able to retrieve reproductive cells that produced immature egg cells when grown in the laboratory. The egg cells, when injected into mice, generated follicles, the ovarian structure in which eggs are formed, as well as mature eggs, some of which had a single set of chromosomes, a signature of eggs and sperm.

The results were published online Sunday by the journal Nature Medicine.

Mr. Tilly and colleagues wrote that their work opens up "a new field in human reproductive biology that was inconceivable less than 10 years ago," and that access to the new cells will make possible novel forms of fertility preservation.

David Albertini, an expert on female reproduction at the Kansas University Medical Center, called the report "a real technological tour de force," but added that it was not yet clear whether the procedure yielded real egg cells that could be used in human fertility.

Even if the research is validated, the immediate use of the cells in question would be to generate egg cells for research use, like testing the effects of drugs. Use in fertility treatments would be far off, Mr. Albertini said, because cells grown in the laboratory often develop abnormalities, a problem that would need correction before any egg could be accepted for fertilization.

First published on February 27, 2012 at 12:00 am

Read more:
Study finds stem cells can create human eggs

Posted in Stem Cell Videos | Comments Off on Study finds stem cells can create human eggs

Women's fertility 'bank account' challenged

Posted: February 27, 2012 at 6:14 am

An experiment that has produced human eggs from stem cells could be a boon for women desperate to have a baby, scientists say.

New research has swept away the belief women only have a limited stock of eggs and replaces it with the theory the supply is continuously replenished from precursor cells in the ovary.

"The prevailing dogma in our field for the better part of the last 50 or 60 years was that young girls at birth were given a bank account of eggs at birth that's not renewable," says Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital in the US, who led the research.

"As they become mature and become a woman, they use those eggs up (and) the ovaries will fail when they enter menopause."

Tilly first challenged the "bank account" doctrine eight years ago, suggesting female mammals continue producing egg-making cells into adulthood rather than from a stock acquired at birth.

His theory ran into a firestorm.

Other scientists challenged the accuracy of his experiments or dismissed their conclusions as worthless, given they were only conducted on lab mice.

But Tilly says the new work not only confirms his controversial idea, it also takes it further.

In it, his team isolated egg-producing stem cells in human ovaries and then coaxed them into developing oocytes, as eggs are called.

Building on a feat by Chinese scientists, they pinpointed the oocyte stem cells by using antibodies which latched onto a protein "handle" located on the side of these cells.

The team tagged the stem cells with a fluorescent green protein - a common trick to help figure out what happens in lab experiments.

The cells were injected into biopsied human ovarian tissue which was then grafted beneath the skin of mice.

Within 14 days, the graft had produced a budding of oocytes. Some of the eggs glowed with the fluorescent tag, proving that they came from the stem cells. But others did not, which suggested they were already present in the tissue before the injection.

Tilly said "the hairs were standing up on my arm" when he saw time-elapse video showing the eggs maturing in a lab dish.

Further testing needs to be done but Tilly says the work could be far-reaching.

Read more:
Women's fertility 'bank account' challenged

Posted in Stem Cell Videos | Comments Off on Women's fertility 'bank account' challenged

Page 2,843«..1020..2,8422,8432,8442,845..2,8502,860..»